Patents by Inventor Philip G. Jones

Philip G. Jones has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Compounds and compositions and uses thereof
    Patent number: 11958862
    Abstract: Disclosed are compounds of formula (I): and pharmaceutical compositions containing such compounds. Methods of treating neurological or psychiatric disease and disorders in a subject in need are also disclosed.
    Type: Grant
    Filed: January 11, 2021
    Date of Patent: April 16, 2024
    Assignees: Sumitomo Pharma America, Inc., PGI Drug Discovery LLC
    Inventors: Linghong Xie, Michele L. R. Heffernan, Philip Glyn Jones, Taleen G. Hanania
  • Substituted cyclopropanes as PDE-10 inhibitors
    Patent number: 10604536
    Abstract: Provided herein are substituted cyclopropane compounds, and pharmaceutical compositions thereof, useful for the treatment of, for example, central nervous system and metabolic diseases and disorders.
    Type: Grant
    Filed: May 11, 2018
    Date of Patent: March 31, 2020
    Assignee: Sunovion Pharamaceuticals Inc.
    Inventors: John Emmerson Campbell, Philip G. Jones, Scott Malcolm
  • HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF
    Publication number: 20190031685
    Abstract: Provided herein are heteroaryl compounds, methods of their synthesis, pharmaceutical compositions comprising the compounds, and methods of their use. In one embodiment, the compounds provided herein are useful for the treatment, prevention, and/or management of various disorders, such as CNS disorders and neurological disorders, including, but not limited to, e.g., psychosis, schizophrenia, depression, movement disorders, and Parkinson's disease.
    Type: Application
    Filed: April 6, 2018
    Publication date: January 31, 2019
    Inventors: Philip G. Jones, Robert Lew, Kerry L. Spear, Linghong Xie
  • HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF
    Publication number: 20180258104
    Abstract: Provided herein are heteroaryl compounds, methods of their synthesis, pharmaceutical compositions comprising the compounds, and methods of their use. In one embodiment, the compounds provided herein are useful for the treatment, prevention, and/or management of various disorders, such as CNS disorders and metabolic disorders, including, but not limited to, e.g., neurological disorders, psychosis, schizophrenia, obesity, and diabetes.
    Type: Application
    Filed: May 11, 2018
    Publication date: September 13, 2018
    Inventors: John Emmerson Campbell, Philip G. Jones, Scott Malcolm
  • Substituted [1,2,4]triazolo[1,5-a]pyrazines as phosphodiesterase inhibitors
    Patent number: 9994590
    Abstract: Provided herein are substituted [1,2,4]triazlolo[1,5-?]pyrazine compounds, and pharmaceutical compositions thereof, useful for the treatment of, for example, central nervous system and metabolic diseases and disorders.
    Type: Grant
    Filed: October 20, 2016
    Date of Patent: June 12, 2018
    Assignee: SUNOVION PHARMACEUTICALS INC.
    Inventors: John Emmerson Campbell, Philip G. Jones, Scott Malcolm
  • D2 receptor modulators and methods of use thereof in the treatment of diseases and disorders
    Patent number: 9951088
    Abstract: Provided herein are heteroaryl compounds, methods of their synthesis, pharmaceutical compositions comprising the compounds, and methods of their use. In one embodiment, the compounds provided herein are useful for the treatment, prevention, and/or management of various disorders, such as CNS disorders and neurological disorders, including, but not limited to, e.g., psychosis, schizophrenia, depression, movement disorders, and Parkinson's disease.
    Type: Grant
    Filed: May 9, 2013
    Date of Patent: April 24, 2018
    Assignee: SUNOVION PHARMACEUTICALS INC.
    Inventors: Philip G. Jones, Robert Lew, Kerry L. Spear, Linghong Xie
  • Novel RGS9 protein binding interactions and methods of use thereof
    Publication number: 20030166850
    Abstract: The present invention relates to novel protein binding interactions, comprising a regulator of G-protein signalling protein (RGS) and a non G-protein binding partner. More particularly, the invention relates to a novel interaction between RGS9 and evectin polypeptides, the use of such polypeptides, as well as the production of such polypeptides. The invention relates also to identifying compounds which may be agonists, antagonists and/or inhibitors of RGS9 and/or evectin polypeptides, and therefore potentially useful in therapy. In particular embodiments, the RGS9 and evectin polypeptides produced are used in methods for assaying the effects of test compounds on the activity of RGS9-evectin dimers, methods for assaying the effects of test compounds on the activity of RGS9-evectin dimers comprised in transgenic animals encoding RGS9 and evectin, methods for diagnosis and treatment of diseases related to the activity of RGS9-evectin dimers and methods for modulating G-protein activity.
    Type: Application
    Filed: March 27, 2002
    Publication date: September 4, 2003
    Applicant: Wyeth
    Inventors: Philip G. Jones, Kathleen H. Young